Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3

NCT03834220 is registered in ClinicalTrials.gov with Debiopharm International SA as lead sponsor.

NCT NCT03834220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03834220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3
Lead sponsor
Debiopharm International SA
Phase
Phase 2
Overall status
Terminated
Start date
March 22, 2019
Completion date
January 4, 2022
Enrollment
63 (actual)
Sites
105

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor